Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galapagos NV

http://www.glpg.com

Latest From Galapagos NV

Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds

Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.

Financing Innovation

Galapagos Says Goodbye To Jyseleca And Streamlines Operations

The Belgium-based biotech is transferring the rights to its only marketed product to Italy’s Alfasigma in a move aimed at cutting costs and tightening its focus on its early-stage immunology and oncology pipeline.

Business Strategies Deals

It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever

But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.

Deals Cancer

Galapagos Could Give Up On Jyseleca Over JAK Class Woes

New chief financial officer Thad Huston said that Galapagos was evaluating “various strategic options for Jyseleca,” the company’s only revenue source, given that the landscape for the JAK class in Europe “has changed significantly over the past six months.”

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
    • Large Molecule
  • Other Names / Subsidiaries
    • Abound Bio, Inc.
    • CellPoint B.V.
    • Discovery Partners International
    • Inpharmatica Ltd.
    • Sareum Holdings plc.
    • ProSkelia
UsernamePublicRestriction

Register